Zhen Shang Selected Research

Acute Myeloid Leukemia (Acute Myelogenous Leukemia)

1/2020	Clinical efficacy of decitabine‑containing induction chemotherapy in de novo non‑elderly acute myeloid leukemia.
1/2020	Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD+ acute myeloid leukemia.
6/2017	MicroRNA 217 inhibits cell proliferation and enhances chemosensitivity to doxorubicin in acute myeloid leukemia by targeting KRAS.
6/2013	[Mutation of isocitrate dehydrogenase 2 (IDH2) gene in Chinese AML patients and its clinical significance].
12/2012	Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.
12/2012	[Detection of isocitrate dehydrogenase 1 gene mutation in 205 AML patients and its clinical significance].
11/2012	Integrative analysis of prognostic factors in Chinese core binding factor leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zhen Shang Research Topics

Disease

7	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 11/2012
3	Neoplasms (Cancer) 10/2021 - 01/2014
3	Leukemia 12/2015 - 11/2012
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022 - 01/2021
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022
1	Kaposi Sarcoma (Kaposi's Sarcoma) 01/2022
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2021
1	Lymphopenia (Lymphocytopenia) 01/2019
1	Multiple Myeloma 01/2018
1	Neuralgia (Stump Neuralgia) 01/2018
1	Pain (Aches) 01/2018
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2018
1	Carcinogenesis 01/2017
1	Cardiotoxicity 01/2014
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2014

Drug/Important Bio-Agent (IBA)

3	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 06/2013 - 12/2012
2	Bortezomib (Velcade)FDA Link 01/2018 - 01/2014
1	Chimeric Antigen ReceptorsIBA 01/2022
1	Circular RNAIBA 10/2021
1	GlucocorticoidsIBA 01/2021
1	Inosine Triphosphate (ITP)IBA 01/2021
1	Decitabine FDA Link 01/2020
1	Tyrosine (L-Tyrosine)FDA Link 01/2020
1	Trace Elements (Biometals)IBA 01/2019
1	ZincIBA 01/2019
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2018
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	MicroRNAs (MicroRNA)IBA 06/2017
1	Doxorubicin (Adriamycin)FDA LinkGeneric 06/2017
1	Transcription Factors (Transcription Factor)IBA 01/2017
1	Transcription Activator-Like Effector NucleasesIBA 12/2015
1	Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA 01/2014
1	Protein Isoforms (Isoforms)IBA 12/2012
1	Biological ProductsIBA 11/2012
1	Core Binding Factors (Core-Binding Factor)IBA 11/2012

Therapy/Procedure

2	Immunotherapy 01/2022 - 01/2021
2	Stem Cell Transplantation 01/2022 - 01/2022
2	Therapeutics 01/2020 - 01/2018
1	Remission Induction 01/2020
1	Induction Chemotherapy 01/2020
1	Transplantation 06/2013